Shire Acquires German Biotech Jerini; Pfizer Makes Big News In Asia
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the In Vivo blog. Visit the blog at http://invivoblog.blogspot.com/.
You may also be interested in...
ViroPharma Makes Smart Bet On Split Indications For HAE With Lev Deal
ViroPharma's proposed acquisition of Lev Pharmaceuticals covers contingencies for the various regulatory outcomes for Lev's crown jewel, the hereditary angioedema therapy Cinryze, including a possible escape hatch
ViroPharma Makes Smart Bet On Split Indications For HAE With Lev Deal
ViroPharma's proposed acquisition of Lev Pharmaceuticals covers contingencies for the various regulatory outcomes for Lev's crown jewel, the hereditary angioedema therapy Cinryze, including a possible escape hatch
Can Out-Partnering Help Vault Pfizer Over the "Second Cliff"?
The industry's genericization problem will seriously constrain Big Pharma's ability to pay for late-stage development on all its products. One potential solution is being developed by Pfizer, whose top R&D execs see out-partnering as a way to free up resources for key programs and to expand R&D capacity. In this interview with R&D boss Martin Mackay, Mackay reports that Pfizer is building up a war-chest of out-licensing and partnering candidates, pursuing a wide variety of transactions--including project financing, straight out-licensing and spinoffs. But the extent of Pfizer's long-term commitment to out-partnering still isn't clear.